0001567619-19-023074.txt : 20191213 0001567619-19-023074.hdr.sgml : 20191213 20191213164010 ACCESSION NUMBER: 0001567619-19-023074 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20191213 FILED AS OF DATE: 20191213 DATE AS OF CHANGE: 20191213 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kirk Julian P. CENTRAL INDEX KEY: 0001559726 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-31564 FILM NUMBER: 191285054 MAIL ADDRESS: STREET 1: THE GOVERNOR TYLER STREET 2: 1881 GROVE AVENUE CITY: RADFORD STATE: VA ZIP: 24141 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Fibrocell Science, Inc. CENTRAL INDEX KEY: 0000357097 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 870458888 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 405 EAGLEVIEW BOULEVARD CITY: EXTON STATE: PA ZIP: 19341 BUSINESS PHONE: 484-713-6000 MAIL ADDRESS: STREET 1: 405 EAGLEVIEW BOULEVARD CITY: EXTON STATE: PA ZIP: 19341 FORMER COMPANY: FORMER CONFORMED NAME: ISOLAGEN INC DATE OF NAME CHANGE: 20020320 FORMER COMPANY: FORMER CONFORMED NAME: AMERICAN FINANCIAL HOLDING INC /DE DATE OF NAME CHANGE: 19960330 FORMER COMPANY: FORMER CONFORMED NAME: AMERICAN FINANCIAL HOLDING INC /CO DATE OF NAME CHANGE: 19921008 4 1 doc1.xml FORM 4 X0306 4 2019-12-13 1 0000357097 Fibrocell Science, Inc. FCSC 0001559726 Kirk Julian P. C/O THIRD SECURITY, LLC 1881 GROVE AVENUE RADFORD VA 24141 1 0 0 0 Option to Purchase Common Stock 75.00 2019-12-13 4 D 0 534 D 2022-10-30 Common Stock 534 0 D Option to Purchase Common Stock 82.35 2019-12-13 4 D 0 1600 D 2023-07-19 Common Stock 1600 0 D Option to Purchase Common Stock 62.10 2019-12-13 4 D 0 1200 D 2024-06-20 Common Stock 1200 0 D Option to Purchase Common Stock 81.60 2019-12-13 4 D 0 2400 D 2025-06-24 Common Stock 2400 0 D Option to Purchase Common Stock 14.25 2019-12-13 4 D 0 2400 D 2026-06-22 Common Stock 2400 0 D Option to Purchase Common Stock 16.55 2019-12-13 4 D 0 6000 D 2027-06-22 Common Stock 6000 0 D Option to Purchase Common Stock 2.36 2019-12-13 4 D 0 6000 D 2028-06-19 Common Stock 6000 0 D Option to Purchase Common Stock 1.94 2019-12-13 4 D 0 12000 D 2029-06-12 Common Stock 12000 0 D Pursuant to the Agreement and Plan of Merger, dated as of September 12, 2019 (the "Merger Agreement"), among Fibrocell Science, Inc. (the "Company"), Castle Creek Pharmaceutical Holdings, Inc. and Castle Creek Merger Corp., effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, outstanding options, whether vested or not, became fully vested in accordance with the terms of the Merger Agreement and were canceled in exchange for a cash payment equal to the number of shares of Company common stock underlying the options multiplied by the excess of the per share merger consideration of $3.00 over the per share exercise price. /s/ Julian P. Kirk 2019-12-13